Fifthly, the addition of anti-PD1/PDL1 antibodies to radical treatment has improved the prognosis of non-metastatic NSCLC, melanoma, renal cell cancer, bladder cancer, and triple-negative breast cancer. Here, PDCD1 is linked to triple-negative breast carcinoma.